CJC-1295 vs Sermorelin
Both are GHRH analogs based on the GRF 1-29 sequence, so they share a mechanism. The difference is stability: CJC-1295 (no DAC) is a modified, more durable version, while sermorelin is the shorter-acting original.
| CJC-1295 (no DAC) | Sermorelin | |
|---|---|---|
| Compound class | GHRH analog (mod GRF 1-29) | GHRH analog (GRF 1-29) |
| Primary target | GHRH receptor | GHRH receptor |
| Category | Growth Hormone | Growth Hormone |
| Administration | Subcutaneous, 1-3x daily | Subcutaneous, daily |
| Research focus | Amplified GH pulse amplitude | Foundational GH-axis research |
Key differences
- Half-life: sermorelin clears very quickly (minutes); CJC-1295 (no DAC) is modified for somewhat greater stability.
- Mechanism: both stimulate the GHRH receptor to amplify GH pulses — the structural modification is what differs.
- Research role: sermorelin is the foundational GH-axis tool; CJC-1295 is the more potent, longer-reaching descendant.
- Both are subcutaneous, dosed daily, and frequently paired with a GHRP.
Which is right for your research?
Sermorelin is the classic, short-acting GHRH reference; CJC-1295 (no DAC) is the more durable modern analog when a stronger, longer pulse is the goal.
Frequently asked questions
Are CJC-1295 and sermorelin the same kind of peptide?
Yes — both are GHRH analogs based on GRF 1-29. CJC-1295 (no DAC) is a modified, more stable version, while sermorelin is the shorter-acting original.
Which lasts longer?
CJC-1295 (no DAC) is engineered for greater stability than sermorelin, which clears within minutes.
Can either be combined with a GHRP?
Yes. Both are commonly paired with a GHRP such as ipamorelin to produce a larger combined GH pulse.
For Research Use Only. All products are sold as research chemicals for in-vitro laboratory study. Not for human consumption, medical, veterinary, or household use.